SQZ Biotechnologies Company
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SQZ Biotechnologies Company
The industry has witnessed a lot of progress with cell therapies for blood cancers. The next critically important goal must be to find a safe and effective pathway for cell therapies in patients with solid tumors.
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
- Site Specific
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- SQZ Biotech